{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:12:37Z","timestamp":1793146357035,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant Number 82141114, 81972339 (Z.B.W.)"],"award-info":[{"award-number":["Grant Number 82141114, 81972339 (Z.B.W.)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Research Center for Translational Medicine","award":["grant number NRCTM (SH)- 2019-05 (Z.B.W.)"],"award-info":[{"award-number":["grant number NRCTM (SH)- 2019-05 (Z.B.W.)"]}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Grant Number 18XD1403400 (Z.B.W.)"],"award-info":[{"award-number":["Grant Number 18XD1403400 (Z.B.W.)"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11060-025-04949-7","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:30:18Z","timestamp":1738387818000},"page":"587-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance"],"prefix":"10.1007","volume":"172","author":[{"given":"Weiting","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhebao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"4949_CR1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"Ezzat S, Asa SL, Couldwell WT et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613\u2013619","journal-title":"Cancer"},{"key":"4949_CR2","first-page":"30","volume":"15","author":"EV Varlamov","year":"2019","unstructured":"Varlamov EV, McCartney S, Fleseriu M (2019) Functioning pituitary adenomas\u2013current treatment options and emerging medical therapies. Eur Endocrinol 15:30","journal-title":"Eur Endocrinol"},{"key":"4949_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A et al (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33:6\u201326","journal-title":"Endocr Pathol"},{"key":"4949_CR4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41379-021-00820-y","volume":"34","author":"SL Asa","year":"2021","unstructured":"Asa SL, Mete O, Cusimano MD et al (2021) Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 34:1634\u20131650","journal-title":"Mod Pathol"},{"key":"4949_CR5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000504000","volume":"110","author":"S Lin","year":"2020","unstructured":"Lin S, Zhang A, Zhang X et al (2020) Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications. Neuroendocrinology 110:477\u2013488","journal-title":"Neuroendocrinology"},{"key":"4949_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42\u201350","journal-title":"Neuroendocrinology"},{"key":"4949_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23:27\u201337","journal-title":"Pituitary"},{"key":"4949_CR8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/ijms22041743","volume":"22","author":"NV Popova","year":"2021","unstructured":"Popova NV, J\u00fccker M (2021) The role of mTOR signaling as a therapeutic target in cancer. Int J Mol Sci 22:1743","journal-title":"Int J Mol Sci"},{"key":"4949_CR9","first-page":"5833","volume":"11","author":"Q Wang","year":"2021","unstructured":"Wang Q, Wang J, Xiang H et al (2021) The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers. Am J Cancer Res 11:5833","journal-title":"Am J Cancer Res"},{"key":"4949_CR10","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.3390\/ijms241310952","volume":"24","author":"A Derwich","year":"2023","unstructured":"Derwich A, Sykutera M, Bromi\u0144ska B et al (2023) The role of activation of PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways in aggressive pituitary adenomas\u2014new potential therapeutic approach\u2014a systematic review. Int J Mol Sci 24:10952","journal-title":"Int J Mol Sci"},{"key":"4949_CR11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D, Way JS, Zhang X et al (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104:1929\u20131936","journal-title":"J Clin Endocrinol Metab"},{"key":"4949_CR12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2019.05.043","volume":"459","author":"H Yao","year":"2019","unstructured":"Yao H, Tang H, Zhang Y et al (2019) DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma. Cancer Lett 459:135\u2013144","journal-title":"Cancer Lett"},{"key":"4949_CR13","doi-asserted-by":"crossref","first-page":"39329","DOI":"10.18632\/oncotarget.5744","volume":"6","author":"SJ Lin","year":"2015","unstructured":"Lin SJ, Leng ZG, Guo YH et al (2015) Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline. Oncotarget 6:39329","journal-title":"Oncotarget"},{"key":"4949_CR14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/neuonc\/noac053","volume":"24","author":"H Yao","year":"2022","unstructured":"Yao H, Xie W, Dai Y et al (2022) TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT. Neuro Oncol 24:1286\u20131297","journal-title":"Neuro Oncol"},{"key":"4949_CR15","first-page":"1","volume":"2022","author":"K Fan","year":"2022","unstructured":"Fan K, Ding X, Zang Z et al (2022) Drp1-mediated mitochondrial metabolic dysfunction inhibits the tumor growth of pituitary adenomas. Oxid Med Cell Longev 2022:1","journal-title":"Oxid Med Cell Longev"},{"key":"4949_CR16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 world health organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521\u2013535","journal-title":"Acta Neuropathol"},{"key":"4949_CR17","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R et al (2014) IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE 9:e96801","journal-title":"PLoS ONE"},{"key":"4949_CR18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283\u2013296","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4949_CR19","first-page":"92","volume-title":"mTOR: Role in cancer, metastasis and drug resistance","author":"AK Murugan","year":"2019","unstructured":"Murugan AK (2019) mTOR: Role in cancer, metastasis and drug resistance. Seminars in cancer biology, Elsevier, Amsterdem, pp 92\u2013111"},{"key":"4949_CR20","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1210\/jc.2017-00627","volume":"102","author":"SJ Lin","year":"2017","unstructured":"Lin SJ, Wu ZR, Cao L et al (2017) Pituitary tumor suppression by combination of cabergoline and chloroquine. J Clin Endocrinol Metab 102:3692\u20133703","journal-title":"J Clin Endocrinol Metab"},{"key":"4949_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15586\/aei.v51i1.739","volume":"51","author":"Y-L Tang","year":"2023","unstructured":"Tang Y-L, Zhu L, Yang H-F et al (2023) Research progress on the role of Ndfip1 (Nedd4 family interacting protein 1) in immune cells. Allergol Immunopathol 51:77\u201383","journal-title":"Allergol Immunopathol"},{"key":"4949_CR22","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1073\/pnas.1322739111","volume":"111","author":"JA Altin","year":"2014","unstructured":"Altin JA, Daley SR, Howitt J et al (2014) Ndfip1 mediates peripheral tolerance to self and exogenous antigen by inducing cell cycle exit in responding CD4+ T cells. Proc Natl Acad Sci 111:2067\u20132074","journal-title":"Proc Natl Acad Sci"},{"key":"4949_CR23","doi-asserted-by":"crossref","first-page":"11226","DOI":"10.1038\/ncomms11226","volume":"7","author":"CE O\u2019Leary","year":"2016","unstructured":"O\u2019Leary CE, Riling CR, Spruce LA et al (2016) Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4+ effector T cells. Nat Commun 7:11226","journal-title":"Nat Commun"},{"key":"4949_CR24","doi-asserted-by":"crossref","first-page":"15677","DOI":"10.1038\/ncomms15677","volume":"8","author":"AAK Layman","year":"2017","unstructured":"Layman AAK, Deng G, O\u2019Leary CE et al (2017) Ndfip1 restricts mTORC1 signalling and glycolysis in regulatory T cells to prevent autoinflammatory disease. Nat Commun 8:15677","journal-title":"Nat Commun"},{"key":"4949_CR25","first-page":"927","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang C, Zhao Q et al (2019) The miR-873\/NDFIP1 axis promotes hepatocellular carcinoma growth and metastasis through the AKT\/mTOR-mediated Warburg effect. Am J Cancer Res 9:927","journal-title":"Am J Cancer Res"},{"key":"4949_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0803-3","volume":"17","author":"N Haddadi","year":"2018","unstructured":"Haddadi N, Lin Y, Travis G et al (2018) PTEN\/PTENP1:\u2019Regulating the regulator of RTK-dependent PI3K\/Akt signalling\u2019, new targets for cancer therapy. Mol Cancer 17:1\u201314","journal-title":"Mol Cancer"},{"key":"4949_CR27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/15548627.2015.1009767","volume":"11","author":"J-H Chen","year":"2015","unstructured":"Chen J-H, Zhang P, Chen W-D et al (2015) ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy 11:239\u2013252","journal-title":"Autophagy"},{"key":"4949_CR28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/leu.2011.46","volume":"25","author":"A Martelli","year":"2011","unstructured":"Martelli A, Evangelisti C, Chappell W et al (2011) Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway. Leukemia 25:1064\u20131079","journal-title":"Leukemia"},{"key":"4949_CR29","doi-asserted-by":"crossref","first-page":"ra70","DOI":"10.1126\/scisignal.2003084","volume":"5","author":"U Putz","year":"2012","unstructured":"Putz U, Howitt J, Doan A et al (2012) The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Science Signaling 5:ra70\u2013ra70","journal-title":"Science Signaling"},{"key":"4949_CR30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1083\/jcb.201105009","volume":"196","author":"J Howitt","year":"2012","unstructured":"Howitt J, Lackovic J, Low L-H et al (2012) Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia. J Cell Biol 196:29\u201336","journal-title":"J Cell Biol"},{"key":"4949_CR31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jmcb\/mjv020","volume":"7","author":"J Howitt","year":"2015","unstructured":"Howitt J, Low L-H, Putz U et al (2015) Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. J Mol Cell Biol 7:119\u2013131","journal-title":"J Mol Cell Biol"},{"key":"4949_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neulet.2013.09.017","volume":"555","author":"C-P Goh","year":"2013","unstructured":"Goh C-P, Low L-H, Putz U et al (2013) Ndfip1 expression in developing neurons indicates a role for protein ubiquitination by Nedd4 E3 ligases during cortical development. Neurosci Lett 555:225\u2013230","journal-title":"Neurosci Lett"},{"key":"4949_CR33","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1093\/cercor\/bht191","volume":"24","author":"VE Hammond","year":"2014","unstructured":"Hammond VE, Gunnersen JM, Goh C-P et al (2014) Ndfip1 is required for the development of pyramidal neuron dendrites and spines in the neocortex. Cereb Cortex 24:3289\u20133300","journal-title":"Cereb Cortex"},{"key":"4949_CR34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11102-023-01340-5","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Geer EB, Lala N et al (2023) The treatment of aggressive prolactinomas with everolimus. Pituitary 26:474\u2013481","journal-title":"Pituitary"},{"key":"4949_CR35","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E, Juraschka K, Tateno T et al (2014) The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 21:R331\u2013R344","journal-title":"Endocr Relat Cancer"},{"key":"4949_CR36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/hmg\/ddy396","volume":"28","author":"CM Gorvin","year":"2019","unstructured":"Gorvin CM, Newey PJ, Rogers A et al (2019) Association of prolactin receptor (PRLR) variants with prolactinomas. Hum Mol Genet 28:1023\u20131037","journal-title":"Hum Mol Genet"},{"key":"4949_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/ERC-21-0215","volume":"29","author":"J Zhu","year":"2022","unstructured":"Zhu J, Tang C, Cong Z et al (2022) ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways. Endocr Relat Cancer 29:33\u201346","journal-title":"Endocr Relat Cancer"},{"key":"4949_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.expneurol.2013.11.017","volume":"252","author":"C-P Goh","year":"2014","unstructured":"Goh C-P, Putz U, Howitt J et al (2014) Nuclear trafficking of Pten after brain injury leads to neuron survival not death. Exp Neurol 252:37\u201346","journal-title":"Exp Neurol"},{"key":"4949_CR39","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s11064-023-03862-7","volume":"48","author":"L He","year":"2023","unstructured":"He L, Chang Q, Zhang Y et al (2023) MiR-155-5p aggravated astrocyte activation and glial scarring in a spinal cord injury model by inhibiting Ndfip1 expression and PTEN nuclear translocation. Neurochem Res 48:1912\u20131924","journal-title":"Neurochem Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T10:28:58Z","timestamp":1743848938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4949"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04949-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human sample: The study was conducted in accordance with ethical guidelines and received approval from the Ethical Review Board at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China). Mouse model: The study was approved by the Ethical Review Board at Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, with the ethics number: RJ2023009.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}